Oral Oncology
Volume 46, Issue 4 , Pages 302-306 , April 2010

The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis

  • Yu-Wei Chiu

      Affiliations

    • School of Dentistry, National Yang-Ming University, Taipei, Taiwan
    • Department of Stomatology, Taipei-Veterans General Hospital, Taiwan
    • ,
  • Hsi-Feng Tu

      Affiliations

    • School of Dentistry, National Yang-Ming University, Taipei, Taiwan
    • ,
  • I-Kai Wang

      Affiliations

    • School of Dentistry, National Yang-Ming University, Taipei, Taiwan
    • Department of Stomatology, Taipei-Veterans General Hospital, Taiwan
    • ,
  • Cheng-Hsien Wu

      Affiliations

    • School of Dentistry, National Yang-Ming University, Taipei, Taiwan
    • Department of Stomatology, Taipei-Veterans General Hospital, Taiwan
    • ,
  • Kuo-Wei Chang

      Affiliations

    • School of Dentistry, National Yang-Ming University, Taipei, Taiwan
    • Department of Stomatology, Taipei-Veterans General Hospital, Taiwan
    • ,
  • Tsung-Yun Liu

      Affiliations

    • Medical Education, Taipei-Veterans General Hospital, Taiwan
    • ,
  • Shou-Yen Kao

      Affiliations

    • School of Dentistry, National Yang-Ming University, Taipei, Taiwan
    • Department of Stomatology, Taipei-Veterans General Hospital, Taiwan
    • Corresponding Author InformationCorresponding author. Address: No. 201, Sec II, Shih-Pai Rd., Department of Stomatology, Taipei-Veterans General Hospital, Taipei, Taiwan. Tel.: +886 2 28757572; fax: +886 2 28742375.

Received 7 December 2009 ,Revised 22 January 2010 ,Accepted 22 January 2010.

Reference 

  1. Chellaiah MA, Kizer N, Biswas R, et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell. 2003;14(1):173–189
  2. Ishijima M, Rittling SR, Yamashita T, et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med. 2001;193(3):399–404
  3. Patarca R, Freeman GJ, Singh RP, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med. 1989;170(1):145–161
  4. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res. 2004;121(2):228–241
  5. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006;17(6):463–474
  6. D′Alfonso S, Barizzone N, Giordano M, et al. Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2005;52(2):539–547
  7. Hummelshoj T, Ryder LP, Madsen HO, Odum N, Svejgaard A. A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol. 2006;43(7):980–986
  8. Mochida S, Hashimoto M, Matsui A, et al. Genetic polymorphism in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun. 2004;313(4):1079–1085
  9. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Biol. 2006;16(2):79–87
  10. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem. 2004;279(12):11051–11064
  11. Lin YH, Yang-Yen HF. The osteopontin–CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276(49):46024–46030
  12. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10(1 Pt 1):184–190
  13. Donati V, Boldrini L, Dell’Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 2005;11(18):6459–6465
  14. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2006;118(9):2255–2261
  15. Department of Health EY ROCT. Ranking of cancer mortality in Taiwan; 2007.
  16. Department of Health EY ROCT. Cancer registry annual report in Taiwan area; 2007.
  17. Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for allelic associations. Human Hered. 2000;50(2):133–139
  18. Zhao JH, Lissarrague S, Essioux L, Sham PC. GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics (Oxford, England). 2002;18(12):1694–1695
  19. Zhao JH, Sham PC. Faster haplotype frequency estimation using unrelated subjects. Human Hered. 2002;53(1):36–41
  20. Zhao JH, Sham PC. Generic number systems and haplotype analysis. Comput Meth Programs Biomed. 2003;70(1):1–9
  21. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348
  22. Xuan JW, Hota C, Shigeyama Y, D’Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginine–glycine–aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem. 1995;57(4):680–690
  23. Teti A, Farina AR, Villanova I, et al. Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer. 1998;77(1):82–93
  24. Celetti A, Testa D, Staibano S, et al. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res. 2005;11(22):8019–8027
  25. Muramatsu T, Shima K, Ohta K, et al. Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleotides. Cancer Lett. 2005;217(1):87–95
  26. Kita Y, Natsugoe S, Okumura H, et al. Expression of osteopontin in oesophageal squamous cell carcinoma. Br J Cancer. 2006;95(5):634–638
  27. Barnes GL, Javed A, Waller SM, et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res. 2003;63(10):2631–2637

PII: S1368-8375(10)00031-X

doi: 10.1016/j.oraloncology.2010.01.018

Oral Oncology
Volume 46, Issue 4 , Pages 302-306 , April 2010

Article Tools

* Image Usage & Resolution